Center for Injury Research and Prevention

The Changing Landscape of Pediatric Migraine Therapy: A Review

TitleThe Changing Landscape of Pediatric Migraine Therapy: A Review
Publication TypeJournal Article
Year of Publication2018
AuthorsPatterson-Gentile C, Szperka CL
JournalJAMA Neurol
Volume75
Issue7
Pagination881-887
Date Published07/2018
ISSN2168-6157
KeywordsAdolescent, Adrenergic beta-Antagonists, Amitriptyline, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Anticonvulsants, Calcium Channel Blockers, Child, Cognitive Behavioral Therapy, Dihydroergotamine, Dopamine Antagonists, Fluid Therapy, Glucocorticoids, Headache Disorders, Secondary, Humans, Magnesium, Migraine Disorders, Nerve Block, Topiramate, Tryptamines, Valproic Acid
Abstract

Importance: Migraine is a disabling and prevalent condition that affects the pediatric and adolescent population. This review describes current acute and preventive migraine pharmacologic therapies for the pediatric and adolescent population.

Observations: Multiple pharmacotherapies that have been used in the treatment of acute headache and prevention in pediatric migraine are reviewed. There have been recent advances in the management of migraines among pediatric and adolescent patients, including US Food and Drug Administration approval of triptans for acute management in children as young as 6 years, and the first prospective, randomized, double-blind, placebo-controlled comparative study of preventive pharmacotherapy in pediatric migraine. A major challenge of evidence-based research in pediatric and adolescent migraine is the significant placebo effect.

Conclusions and Relevance: Although progress is being made in the management of migraines among pediatric and adolescent patients, there remains much work to be done.

DOI10.1001/jamaneurol.2018.0046
Alternate JournalJAMA Neurol
PubMed ID29532087